Condition
Malignant Peritoneal Mesothelioma
Estimated Enrollment: 35
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment
Study ID Numbers: 12-0032|NCI-2012-00332
Study First Received: May 3, 2012
Last Updated: June 24, 2016
Estimated Primary Completion Date: June 2017
Primary Outcome Measures:
Objective response rate according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1|PFS|OS|Toxicity in terms of adverse events per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) criteria version 4.0|Disease control rate – SD + PR + CR|Percentage of patients who have activating EGFR mutations among all screened patients
Sponsors and Collaborators:
University of Chicago|National Cancer Institute (NCI)
Website Link: https://ClinicalTrials.gov/show/NCT01592383
